Diabetic Foot Ulcer, Peripheral Arterial Disease
Conditions
Keywords
Peripheral arterial disease, diabetic foot ulcer, PAD, DFU
Brief summary
This Phase 1, multicenter, open-label, dose-escalation study evaluated the safety and tolerability of intramuscular administration of PDA-002 (human placenta-derived cells) in subjects with peripheral arterial disease (PAD) and diabetic foot ulcers (DFU).
Detailed description
The purpose of this Phase 1 study was to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of PDA-002, a human placenta-derived cell therapy, administered by intramuscular injection in subjects with peripheral arterial disease (PAD) and diabetic foot ulcers (DFU). This was a multicenter, open-label, 3+3 dose-escalation study. Subjects received PDA-002 administered intramuscularly on Study Days 1 and 8 at 1 of 4 planned dose levels ranging from 3 × 10\^6 to 100 × 10\^6 cells. Dose escalation proceeded after review of safety data from previously enrolled subjects. Subjects were followed for safety assessments for up to 24 months.
Interventions
BIOLOGICALPDA-002
Human placenta-derived cells administered intramuscularly on Study Days 1 and 8.
Sponsors
Celularity Incorporated
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Subjects must satisfy the following criteria to be enrolled in the study: 1. Males and females, 18 to 80 years of age at the time of signing the informed consent document. 2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. Diabetes mellitus type 1 or 2 5. Ischemic or neuro-ischemic diabetic foot ulcer with severity of Grade 1 (full thickness only) or Grade 2 on the Wagner Grading Scale (Appendix A) of greater than one month duration which has not adequately responded to conventional ulcer therapy. 6. Peripheral arterial disease with ankle-brachial index \> 0.5 and ≤ 0.9 or toe-brachial index \> 0.35 and ≤ 0.7. 7. No planned revascularization or amputation over the next 3 months after Screening visit, in the opinion of the Investigator. 8. Screening should not begin until at least 2 weeks after a failed reperfusion intervention and at least 2 months after a successful mechanical intervention. 9. Subject can have stable angina, (Canadian Cardiovascular Society (CCS) Class I-II angina (Appendix H). 10. Subjects should be receiving appropriate medical therapy for hypertension and diabetes. 11. A female of childbearing potential \[FCBP\] must have a negative serum pregnancy test at Screening and a negative urine pregnancy test prior to treatment with study therapy. In addition, sexually active FCBP must agree to use 2 of the following adequate forms of contraception methods simultaneously such as: oral, injectable, or implantable hormonal contraception; tubal ligation; intrauterine device \[IUD\]; barrier contraceptive with spermicide or vasectomized partner for the duration of the study and the follow-up period. 12. Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP for the duration of the study and the follow-up period.
Exclusion criteria
* The presence of any of the following will exclude a subject from enrollment: 1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he or she were to participate in the study. 3. Any condition that confounds the ability to interpret data from the study. 4. Subjects whom, in the judgment of the Investigator, are at elevated risk for the development of a malignancy. This judgment may be based on family history, history of industrial exposures, smoking history or other cancer risk factors. 5. Known to be positive for human immunodeficiency virus. 6. Pregnant or lactating females. 7. Subjects with a body mass index \> 40 at Screening. 8. Aspartate transaminase (AST) or Alanine transaminase (ALT) \> 2.5 x the upper limit of normal (ULN) at Screening. 9. Estimated Glomerular Filtration Rate (eGFR) \< 45 mL/min/1.73 m2 at Screening calculated using the Modification of Diet in Renal Disease Study equation (Levey, 2006) or history of eGFR decline \> 15 mL/min/1.73 m2 in the past year. 10. Alkaline phosphatase \> 2.5 x the ULN at Screening. 11. Bilirubin level \> 2 mg/dL (unless subject has known Gilbert's disease) at Screening. 12. Untreated chronic infection or treatment of any infection with systemic antibiotics, including the ulcer site, within 4 weeks prior to dosing with investigational product \[IP\]. 13. Known osteomyelitis. 14. Ulcer that has decreased or increased in size by ≥ 50% during the screening period. 15. Uncontrolled hypertension (defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 180 mmHg during Screening at 2 independent measurements taken while subject is sitting and resting for at least 5 minutes). 16. Poorly controlled diabetes mellitus (hemoglobin A1c \> 9%). 17. Untreated proliferative retinopathy. 18. History of malignant ventricular arrhythmia, CCS Class III-IV angina pectoris, myocardial infarction/PCI (percutaneous coronary intervention)/CABG (coronary artery bypass graft) in the preceding 6 months, pending coronary revascularization in the following 2 months, transient ischemic attack/cerebrovascular accident in the preceding 6 months, and/or New York Heart Association \[NYHA\] Stage III or IV congestive heart failure, (Appendix C). 19. Abnormal ECG: new bundle branch block (BBB) ≥ 120 msec in the preceding 3 months; QTcB and/or QTcF \> 480 msec or QTcB and/or QTcF ≥ 500 msec with old BBB. Patients with a potential risk for Torsades des Pointes should not be enrolled. 20. Uncontrolled hypercoagulation. 21. Life expectancy less than 2 years due to concomitant illnesses. 22. In the opinion of the Investigator, the subject is unsuitable for cellular therapy. 23. History of malignancy within 5 years except basal cell or squamous cell carcinoma of the skin or remote history of cancer now considered cured or positive Pap smear with subsequent negative follow-up. 24. History of hypersensitivity to any of the components of the product formulation (including bovine or porcine products, dextran 40, and dimethyl sulfoxide \[DMSO\]). 25. Disorders or allergies precluding the use of radiographic contrast or renal insufficiency severe enough to contraindicate the use of radiographic contrast. 26. Subject has received an investigational agent -an agent or device not approved by the US Food and Drug Administration (FDA) for marketed use in any indication- within 90 days (or 5 half-lives, whichever is longer) prior to treatment with study therapy or planned participation in another therapeutic study prior to the completion of this study. 27. Subject has received previous gene or cell therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity (DLTs) | Through Day 15 following initial dosing | Number of participants with dose-limiting toxicities following intramuscular administration of PDA-002. Dose-limiting toxicity was used to evaluate maximum tolerated dose. |
| Treatment-Emergent Adverse Events (TEAEs) | From first dose through month 24 | Number of participants with treatment-emergent adverse events following administration of PDA-002. |
Countries
United States
Contacts
STUDY_DIRECTORsharmila koppisetti, MD
Celularity Incorporated
Participant flow
Recruitment details
A total of 15 participants were enrolled across 4 sequential dose-escalation cohorts in this Phase 1 open-label study conducted at multiple sites in the United States.
Pre-assignment details
Participants were assigned sequentially to 1 of 4 dose-escalation cohorts based on order of enrollment. Dose escalation proceeded after review of available safety data from previously enrolled participants.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 67.3 years STANDARD_DEVIATION 6.66 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 14 Participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 2 / 3 | 0 / 3 | 0 / 6 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 2 / 3 | 6 / 6 |
| serious Total, serious adverse events | 2 / 3 | 3 / 3 | 1 / 3 | 1 / 6 |
Outcome results
None listed